Eli Lilly is expanding its collaboration with Insilico Medicine, extending the company’s AI-driven drug discovery strategy into additional therapeutic areas. The multibillion-dollar expansion offers Insilico $115 million upfront, with up to $2.75 billion in development, regulatory, and commercial milestones tied to progress of multiple preclinical-stage assets. The expanded partnership builds on Insilico’s public pipeline, including programs in idiopathic pulmonary fibrosis and inflammatory bowel disease that have already reached phase 2 development. Insilico also maintains broader targets across cancer, lung, and metabolic diseases. For the industry, the deal signals continued appetite from large biopharma to outsource parts of early discovery—particularly target selection and lead generation—using AI-enabled workflows while bringing candidates back into Lilly’s clinical development engine. The transaction also reflects the intensifying competition among AI-first biotech platforms and traditional drugmakers’ efforts to reduce the time and cost of identifying lead series before clinical trials.